RJFSA
TGTX icon

Raymond James Financial Services Advisors’s TG Therapeutics TGTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.55M Sell
108,969
-304
-0.3% -$6.64K ﹤0.01% 1605
2024
Q2 		$1.94M Buy
109,273
+1,853
+2% +$29.6K ﹤0.01% 1684
2024
Q1 		$1.63M Buy
107,420
+4,548
+4% +$72.5K ﹤0.01% 1750
2023
Q4 		$1.76M Buy
102,872
+4,011
+4% +$46.6K ﹤0.01% 1645
2023
Q3 		$826K Sell
98,861
-4,715
-5% -$65.7K ﹤0.01% 2023
2023
Q2 		$2.57M Buy
103,576
+1,291
+1% +$33.3K ﹤0.01% 1381
2023
Q1 		$1.54M Buy
102,285
+3,696
+4% +$56.1K ﹤0.01% 1647
2022
Q4 		$1.17M Sell
98,589
-659
-0.7% -$4.78K ﹤0.01% 1737
2022
Q3 		$588K Sell
99,248
-1,918
-2% -$12.6K ﹤0.01% 2150
2022
Q2 		$430K Sell
101,166
-12,187
-11% -$76.1K ﹤0.01% 2369
2022
Q1 		$1.08M Buy
113,353
+987
+0.9% +$11.4K ﹤0.01% 1893
2021
Q4 		$2.13M Sell
112,366
-30
-0% -$779 ﹤0.01% 1497
2021
Q3 		$3.74M Sell
112,396
-3,147
-3% -$97.4K 0.01% 1126
2021
Q2 		$4.48M Sell
115,543
-4,415
-4% -$173K 0.01% 1026
2021
Q1 		$5.78M Sell
119,958
-3,435
-3% -$165K 0.01% 839
2020
Q4 		$6.42M Buy
123,393
+4,400
+4% +$149K 0.02% 728
2020
Q3 		$3.18M Sell
118,993
-6,807
-5% -$157K 0.01% 955
2020
Q2 		$2.45M Sell
125,800
-6,823
-5% -$110K 0.01% 1021
2020
Q1 		$1.3M Sell
132,623
-27,826
-17% -$351K 0.01% 1079
2019
Q4 		$1.78M Buy
160,449
+6,745
+4% +$51.3K 0.01% 1222
2019
Q3 		$863K Sell
153,704
-242
-0.2% -$1.69K ﹤0.01% 1556
2019
Q2 		$1.33M Sell
153,946
-10,533
-6% -$79.6K 0.01% 1330
2019
Q1 		$1.32M Buy
164,479
+21,139
+15% +$114K 0.01% 1295
2018
Q4 		$588K Sell
143,340
-2,255
-2% -$11.2K ﹤0.01% 1566
2018
Q3 		$815K Buy
145,595
+1,359
+0.9% +$15.5K ﹤0.01% 1589
2018
Q2 		$1.9M Buy
144,236
+5,165
+4% +$71K 0.01% 1053
2018
Q1 		$1.98M Buy
139,071
+687
+0.5% +$8.78K 0.01% 938
2017
Q4 		$1.14M Buy
138,384
+57,280
+71% +$500K 0.01% 1219
2017
Q3 		$961K Buy
81,104
+31,958
+65% +$364K 0.01% 1338
2017
Q2 		$494K Buy
49,146
+4,240
+9% +$47.5K ﹤0.01% 1681
2017
Q1 		$523K Buy
44,906
+14,068
+46% +$101K ﹤0.01% 1540
2016
Q4 		$143K Buy
+30,838
New +$181K ﹤0.01% 2136

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's TGTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its TG Therapeutics (TGTX) stake by 0.28% in Q3 2024, selling an estimated $6.64K and leaving 108,969 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

Raymond James Financial Services Advisors first reported a position in TGTX in Q4 2016 and has held it in 32 quarters since. The position peaked at $6.42M in Q4 2020. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 108,969 shares of TG Therapeutics worth $2.55M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 304 TG Therapeutics shares in Q3 2024, an estimated $6.64K.
  • TG Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1605 holding.
  • Raymond James Financial Services Advisors first reported a position in TG Therapeutics in Q4 2016 and has held it in 32 quarters since.
  • Raymond James Financial Services Advisors's TG Therapeutics position peaked at $6.42M in Q4 2020.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.